Protagenic Therapeutics, Inc.\new Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Protagenic Therapeutics, Inc.\new (PTIX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$83.67 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-07.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2022-04-07
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-06-30 was -$167.34K.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-03-31 was $83.67K, a 37.73% increase year-over-year.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was -$83.67K, a 133.66% decline from fiscal 2020.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $248.55K, a 27.72% decline from fiscal 2019.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was $343.86K.
- Protagenic Therapeutics, Inc.\new fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was -$250.24K, a 374.89% decline from fiscal 2017.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | $0.00 derived: sum of 2 quarters · filed 2022-04-07 | -$167.34K derived: sum of 3 quarters · filed 2022-04-07 | -$83.67K 10-K · filed 2022-04-07 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$167.34K derived: sum of 2 quarters · filed 2021-11-15 | -$83.67K 10-Q · filed 2021-11-15 | $22.98K derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | -$167.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$83.67K 10-Q · filed 2021-08-16 | $22.98K derived: sum of 3 quarters · filed 2021-08-16 | $127.69K derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | $83.67K 10-Q · filed 2021-05-17 | $190.31K derived: sum of 2 quarters · filed 2021-05-17 | $295.03K derived: sum of 3 quarters · filed 2021-05-17 | $271.47K derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | $106.64K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $211.36K derived: sum of 2 quarters · filed 2021-03-25 | $187.80K derived: sum of 3 quarters · filed 2021-03-25 | $248.55K 10-K · filed 2021-03-25 |
| 2020-09-30 | $104.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $81.16K derived: sum of 2 quarters · filed 2020-11-16 | $141.91K 10-Q · filed 2020-11-16 | $144.66K derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | -$23.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $37.19K 10-Q · filed 2020-08-14 | $39.94K derived: sum of 3 quarters · filed 2021-03-25 | $105.15K derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | $60.75K 10-Q · filed 2020-06-18 | $63.50K derived: sum of 2 quarters · filed 2021-03-25 | $128.71K derived: sum of 3 quarters · filed 2021-03-25 | $355.20K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $2.75K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $67.96K derived: sum of 2 quarters · filed 2021-03-25 | $294.45K derived: sum of 3 quarters · filed 2021-03-25 | $343.86K 10-K · filed 2021-03-25 |
| 2019-09-30 | $65.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $291.70K derived: sum of 2 quarters · filed 2019-11-14 | $341.11K 10-Q · filed 2019-11-14 | $73.12K derived: sum of 4 quarters · filed 2020-04-29 |
| 2019-06-30 | $226.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $275.90K 10-Q · filed 2019-08-14 | $7.91K derived: sum of 3 quarters · filed 2020-04-29 | $7.44K derived: sum of 4 quarters · filed 2020-04-29 |
| 2019-03-31 | $49.40K 10-Q · filed 2019-05-16 | -$218.59K derived: sum of 2 quarters · filed 2020-04-29 | -$219.06K derived: sum of 3 quarters · filed 2020-04-29 | -$207.00K derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | -$267.99K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-29 | -$268.46K derived: sum of 2 quarters · filed 2020-04-29 | -$256.40K derived: sum of 3 quarters · filed 2020-04-29 | -$250.24K 10-K · filed 2020-04-29 |
| 2018-09-30 | -$474.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $11.59K derived: sum of 2 quarters · filed 2018-11-08 | $17.75K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $12.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $18.22K 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | $6.16K 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $91.03K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |